{
  "docId": "019de071-3aad-716d-87e6-57feca2aeaf3",
  "docSlug": "2b4775a08c8e376708f38bde257340c9",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 36,
  "pageCount": 42,
  "prevPage": 35,
  "nextPage": 37,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide uses a three-column layout to summarize key business pillars.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-3aad-716d-87e6-57feca2aeaf3/36",
  "deckHref": "/decks/019de071-3aad-716d-87e6-57feca2aeaf3",
  "deckJsonHref": "/decks/019de071-3aad-716d-87e6-57feca2aeaf3.json",
  "deckAnchorHref": "/decks/019de071-3aad-716d-87e6-57feca2aeaf3#slide-36",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.67,
        "y": 0.25
      },
      "kind": "list",
      "text": "Improving financials: Ten blockbuster medicines; Returned to durable revenue and earnings growth; Focus on operating leverage and cash flow",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03fa5adb-2585-4477-92ea-43671ed6d28a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "list",
      "text": "Strong pipeline: 22 Phase III medicines and significant lifecycle projects; Advancing early- and mid-stage pipeline",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87f3385e-e134-40b7-91e0-437494ff6c64",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "list",
      "text": "Global presence: Balanced specialty and primary-care franchises; Leading emerging markets presence with R&D base",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "caf76ab1-b906-4fb7-a3e6-4465ca5f223a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.94,
        "x": 0.03,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "Innovative medicines in Oncology, Rare Diseases & BioPharmaceuticals; Experienced and proven team",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8363ec6-67d1-443e-a6d1-2e2b89577940",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.94,
        "x": 0.03,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1. In H1 2021... 2. Alexion... 3. Last four quarters... 4. Cardiovascular, Renal & Metabolism and Respiratory & Immunology.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9488e881-0fbd-4cc9-aa86-599ad0652461",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.4,
        "x": 0.03,
        "y": 0.12
      },
      "kind": "title",
      "text": "Pipeline-driven transformation",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63bdfb97-b8f2-44d5-b295-6735161894c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.4,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "AstraZeneca in summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6cd2d668-ad5a-49ec-aa53-561feed18f62",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "376a5926-b2e6-4618-9e7b-28ecd41b25fc",
      "evidence": "Improving financials: Ten blockbuster medicines; Returned to durable revenue and earnings growth; Focus on operating leverage and cash flow",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "executive-summary",
      "slug": null,
      "matchId": "75f261d7-8035-4a9c-bba7-67787d091ac3",
      "evidence": "The slide provides a high-level overview of the company's strategic pillars.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 37,
      "from": 21,
      "beatId": "e153daee-719b-4113-901b-2398e780892e",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The document outlines the company's strategic journey and pipeline progress",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}